drugset
drugset / Trial / NCT06133478

Study of the Safety, Tolerability, and Pharmacokinetics of NUV001 Administered Orally to Healthy Adult Participants

NCT06133478 ↗

Phase 1 Completed 32 enrolled Nuvamid SA Anapharm · collabLGD · collabMedpace, Inc. · collab
RandomizedSequentialQuadruple-blindTreatment

Summary

This blinded placebo-controlled study is designed to evaluate the safety, tolerability, and PK in healthy participants of a single- and multiple-doses (SAD and MAD) of a new investigational drug: NUV001

Timeline

Start
2023-11-09
Primary completion
2024-03-01
Completion
2024-04-05

Drugs

EvaluationDrugModalityDoseRoute
Subject NUV001 Unknown — Oral

Indications

No indication recorded.